Here are the DEF 14A proxy statements from Nektar Therapeutics (NKTR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow NKTR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NKTR filings page.
Nektar Therapeutics is asking stockholders to vote at its 2026 virtual annual meeting on June 4, 2026. Proposals include electing CEO Howard W. Robin to the board, amending the 2017 Performance Incentive Plan to add 3,000,000 shares, ratifying Ernst & Young LLP as auditor for 2026, and approving an advisory say-on-pay vote on executive compensation.
The proxy also details board structure, committee responsibilities, related-party review, and ownership data, including 29,679,647 common shares outstanding as of April 6, 2026, and major holders such as FMR LLC with 10.2% of the stock.